Tebentafusp

DRUG11 trials

Conditions

Advanced MelanomaAdvanced or Metastatic Solid TumorsClear Cell Sarcoma (CCS)HLA-A*0201 Positive Cells PresentMelanoma (Skin)Melanoma, UvealMestastatic Uveal MelanomaMetastatic Uveal Melanoma

Phase 1

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

RecruitingNCT05785754

DynamiCure BiotechnologyAdvanced or Metastatic Solid Tumors

Start: 2023-06-28End: 2026-12-31Target: 320Updated: 2025-06-26

Phase 2

Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

Active, not recruitingNCT05315258

University of OxfordMelanoma (Skin), Melanoma, Uveal

Start: 2022-07-25End: 2027-06-30Target: 850Updated: 2025-07-17

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

RecruitingNCT06070012

Diwakar DavarUveal Melanoma

Start: 2025-08-18End: 2030-09-30Target: 44Updated: 2026-02-27

Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

RecruitingNCT06627244

University of MiamiMetastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver

Start: 2025-02-14End: 2031-02-17Target: 30Updated: 2026-02-23

A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma

RecruitingNCT06942442

Sarcoma Alliance for Research through CollaborationClear Cell Sarcoma (CCS), HLA-A*0201 Positive Cells Present

Start: 2025-10-22End: 2030-10-01Target: 47Updated: 2025-12-26

Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma

RecruitingNCT07057596

Grupo Español Multidisciplinar de MelanomaMestastatic Uveal Melanoma

Start: 2025-07-18End: 2027-12-01Target: 19Updated: 2026-03-06

Hepatic radiotherapy added to standard of care for the treatment of HLA A*02:01 positive Metastatic Uveal Melanoma patients

RecruitingCTIS2024-519760-40-00

Fondazione Policlinico Universitario Agostino Gemelli IRCCSmetastatic uveal melanoma HLA A*02:01 positive

Start: 2025-10-14Target: 20Updated: 2025-07-21

Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

RecruitingNCT07276386

H. Lee Moffitt Cancer Center and Research InstituteMetastatic Uveal Melanoma

Start: 2025-12-31End: 2030-12-01Target: 18Updated: 2026-03-31

Phase 3

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

RecruitingNCT05549297

Immunocore LtdAdvanced Melanoma

Start: 2022-12-19End: 2028-07-01Target: 540Updated: 2026-02-25

Adjuvant Tebentafusp in High Risk Ocular Melanoma

RecruitingNCT06246149

European Organisation for Research and Treatment of Cancer - EORTCUveal Melanoma

Start: 2024-11-11End: 2032-11-01Target: 290Updated: 2026-03-04

Unknown Phase

A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp

NCT04960891

Immunocore LtdUveal Melanoma

Updated: 2022-01-21

Related Papers

Recent Advancements in Cell-Based Therapies in Melanoma.

2024-09-124 citations

Comparison of clinical outcomes of stable disease with confirmed tumor reduction and RECIST partial response for tebentafusp in metastatic uveal melanoma (mUM).

Journal of Clinical Oncology2024-06-01

A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM).

Journal of Clinical Oncology2023-06-014 citations